speb/financial-data huggingface dataset:
PHAR balance_sheet (quarterly, 2025-09-30) — Working Capital: 189686000.00
PHAR income_statement (annual, 2025-12-31) — +Operating Expense: 309753000.00
PHAR income_statement (quarterly, 2025-12-31) — +Operating Expense: 83400000.00
PHAR income_statement (annual, 2025-12-31) — +Total Revenue: 376134000.00
PHAR income_statement (quarterly, 2025-12-31) — +Total Revenue: 106500000.00
PHAR balance_sheet (annual, 2025-12-31) — Accounts Payable: 8545000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Accounts Payable: 8545000.00
PHAR balance_sheet (annual, 2025-12-31) — Accounts Receivable: 41767000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Accounts Receivable: 41767000.00
PHAR balance_sheet (annual, 2025-12-31) — Accumulated Depreciation: -36428000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Accumulated Depreciation: -36428000.00
PHAR balance_sheet (annual, 2025-12-31) — Additional Paid In Capital: 513257000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Additional Paid In Capital: 513257000.00
PHAR income_statement (annual, 2025-12-31) — Amortization: 6285000.00
PHAR income_statement (annual, 2025-12-31) — Amortization Of Intangibles Income Statement: 6285000.00
PHAR income_statement (annual, 2025-12-31) — Basic Average Shares: 71275000.00
PHAR income_statement (quarterly, 2025-12-31) — Basic Average Shares: 66250000.00
PHAR income_statement (annual, 2025-12-31) — Basic EPS: 0.04
PHAR income_statement (quarterly, 2025-12-31) — Basic EPS: 0.08
PHAR cash_flow (annual, 2025-12-31) — Beginning Cash Position: 54944000.00
PHAR cash_flow (quarterly, 2025-12-31) — Beginning Cash Position: 132370000.00
PHAR balance_sheet (annual, 2025-12-31) — Buildings And Improvements: 27946000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Buildings And Improvements: 27946000.00
PHAR cash_flow (annual, 2025-12-31) — Capital Expenditure: -755000.00
PHAR cash_flow (quarterly, 2025-12-31) — Capital Expenditure: -269000.00
PHAR cash_flow (annual, 2025-12-31) — Capital Expenditure Reported: -749000.00
PHAR cash_flow (quarterly, 2025-12-31) — Capital Expenditure Reported: -269000.00
PHAR balance_sheet (annual, 2025-12-31) — Capital Lease Obligations: 17720000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Capital Lease Obligations: 17720000.00
PHAR balance_sheet (annual, 2025-12-31) — Capital Stock: 8009000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Capital Stock: 8009000.00
PHAR balance_sheet (annual, 2025-12-31) — Cash And Cash Equivalents: 145305000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Cash And Cash Equivalents: 145305000.00
PHAR balance_sheet (annual, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 179101000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 179101000.00
PHAR cash_flow (annual, 2025-12-31) — Cash Dividends Paid: 0.00
PHAR cash_flow (quarterly, 2025-12-31) — Cash Dividends Paid: 0.00
PHAR cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Financing Activities: 1495000.00
PHAR cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Financing Activities: 1038000.00
PHAR cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Investing Activities: 26253000.00
PHAR cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Investing Activities: -44000.00
PHAR cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Operating Activities: 54708000.00
PHAR cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Operating Activities: 10707000.00
PHAR cash_flow (annual, 2025-12-31) — Change In Inventory: -1288000.00
PHAR cash_flow (quarterly, 2025-12-31) — Change In Inventory: 2215000.00
PHAR cash_flow (annual, 2025-12-31) — Change In Other Working Capital: 902000.00
PHAR cash_flow (quarterly, 2025-12-31) — Change In Other Working Capital: 1920000.00
PHAR cash_flow (annual, 2025-12-31) — Change In Payable: 14126000.00
PHAR cash_flow (quarterly, 2025-12-31) — Change In Payable: 9988000.00
PHAR cash_flow (annual, 2025-12-31) — Change In Payables And Accrued Expense: 14126000.00
PHAR cash_flow (quarterly, 2025-12-31) — Change In Payables And Accrued Expense: 9988000.00
PHAR cash_flow (annual, 2025-12-31) — Change In Receivables: -3355000.00
PHAR cash_flow (quarterly, 2025-12-31) — Change In Receivables: -14808000.00
PHAR cash_flow (annual, 2025-12-31) — Change In Working Capital: 10385000.00
PHAR cash_flow (quarterly, 2025-12-31) — Change In Working Capital: -685000.00
PHAR cash_flow (annual, 2025-12-31) — Changes In Cash: 82454000.00
PHAR cash_flow (quarterly, 2025-12-31) — Changes In Cash: 11700000.00
PHAR balance_sheet (annual, 2025-12-31) — Common Stock: 8009000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Common Stock: 8009000.00
PHAR balance_sheet (annual, 2025-12-31) — Common Stock Equity: 277102000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Common Stock Equity: 277102000.00
PHAR balance_sheet (annual, 2025-12-31) — Construction In Progress: 0.00
PHAR balance_sheet (quarterly, 2025-12-31) — Construction In Progress: 0.00
PHAR income_statement (annual, 2025-12-31) — Cost Of Revenue: 45500000.00
PHAR income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 21100000.00
PHAR balance_sheet (annual, 2025-12-31) — Current Accrued Expenses: 91312000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Current Accrued Expenses: 91312000.00
PHAR balance_sheet (annual, 2025-12-31) — Current Assets: 299469000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Current Assets: 299469000.00
PHAR balance_sheet (annual, 2025-12-31) — Current Capital Lease Obligation: 3369000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Current Capital Lease Obligation: 3369000.00
PHAR balance_sheet (annual, 2025-12-31) — Current Debt: 5336000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Current Debt: 5336000.00
PHAR balance_sheet (annual, 2025-12-31) — Current Debt And Capital Lease Obligation: 8705000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Current Debt And Capital Lease Obligation: 8705000.00
PHAR balance_sheet (annual, 2025-12-31) — Current Liabilities: 115791000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Current Liabilities: 115791000.00
PHAR balance_sheet (annual, 2025-12-31) — Current Provisions: 1187000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Current Provisions: 1187000.00
PHAR cash_flow (annual, 2025-12-31) — Depreciation: 11216000.00
PHAR cash_flow (quarterly, 2025-12-31) — Depreciation: 3206000.00
PHAR cash_flow (annual, 2025-12-31) — Depreciation Amortization Depletion: 11216000.00
PHAR cash_flow (quarterly, 2025-12-31) — Depreciation Amortization Depletion: 3206000.00
PHAR income_statement (annual, 2025-12-31) — Depreciation Amortization Depletion Income Statement: 9209000.00
PHAR cash_flow (annual, 2025-12-31) — Depreciation And Amortization: 11216000.00
PHAR cash_flow (quarterly, 2025-12-31) — Depreciation And Amortization: 3206000.00
PHAR income_statement (annual, 2025-12-31) — Depreciation And Amortization In Income Statement: 9209000.00
PHAR income_statement (annual, 2025-12-31) — Depreciation Income Statement: 2924000.00
PHAR income_statement (annual, 2025-12-31) — Diluted Average Shares: 71275000.00
PHAR income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 75714286.00
PHAR income_statement (annual, 2025-12-31) — Diluted EPS: 0.04
PHAR income_statement (quarterly, 2025-12-31) — Diluted EPS: 0.07
PHAR income_statement (annual, 2025-12-31) — Diluted NI Availto Com Stockholders: 2851000.00
PHAR income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: 5300000.00
PHAR income_statement (annual, 2025-12-31) — EBIT: 23566000.00
PHAR income_statement (quarterly, 2025-12-31) — EBIT: 6200000.00
PHAR income_statement (annual, 2025-12-31) — EBITDA: 34782000.00
PHAR income_statement (quarterly, 2025-12-31) — EBITDA: 9406000.00
PHAR income_statement (annual, 2025-12-31) — Earnings From Equity Interest: 623000.00
PHAR cash_flow (annual, 2025-12-31) — Earnings Losses From Equity Investments: -623000.00
PHAR cash_flow (quarterly, 2025-12-31) — Earnings Losses From Equity Investments: -902000.00
PHAR cash_flow (annual, 2025-12-31) — Effect Of Exchange Rate Changes: 7907000.00
PHAR cash_flow (quarterly, 2025-12-31) — Effect Of Exchange Rate Changes: 1235000.00
PHAR cash_flow (annual, 2025-12-31) — End Cash Position: 145305000.00
PHAR cash_flow (quarterly, 2025-12-31) — End Cash Position: 145305000.00
PHAR balance_sheet (annual, 2025-12-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 6703000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 6703000.00
PHAR cash_flow (annual, 2025-12-31) — Financing Cash Flow: 1495000.00
PHAR cash_flow (quarterly, 2025-12-31) — Financing Cash Flow: 1038000.00
PHAR balance_sheet (annual, 2025-12-31) — Finished Goods: 18214000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Finished Goods: 18214000.00
PHAR cash_flow (annual, 2025-12-31) — Free Cash Flow: 53953000.00
PHAR cash_flow (quarterly, 2025-12-31) — Free Cash Flow: 10438000.00
PHAR cash_flow (annual, 2025-12-31) — Gain Loss On Investment Securities: -2345000.00
PHAR income_statement (annual, 2025-12-31) — Gain On Sale Of Ppe: 0.00
PHAR income_statement (annual, 2025-12-31) — Gain On Sale Of Security: -4880000.00
PHAR balance_sheet (annual, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: 28819000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: 28819000.00
PHAR income_statement (annual, 2025-12-31) — General And Administrative Expense: 110780000.00
PHAR income_statement (quarterly, 2025-12-31) — General And Administrative Expense: 20000000.00
PHAR balance_sheet (annual, 2025-12-31) — Goodwill: 3319000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Goodwill: 3319000.00
PHAR balance_sheet (annual, 2025-12-31) — Goodwill And Other Intangible Assets: 135538000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Goodwill And Other Intangible Assets: 135538000.00
PHAR balance_sheet (annual, 2025-12-31) — Gross PPE: 60399000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Gross PPE: 60399000.00
PHAR income_statement (annual, 2025-12-31) — Gross Profit: 330634000.00
PHAR income_statement (quarterly, 2025-12-31) — Gross Profit: 85400000.00
PHAR income_statement (annual, 2025-12-31) — Impairment Of Capital Assets: 491000.00
PHAR income_statement (annual, 2025-12-31) — Interest Expense: 10719000.00
PHAR income_statement (quarterly, 2025-12-31) — Interest Expense: 1400000.00
PHAR income_statement (annual, 2025-12-31) — Interest Expense Non Operating: 10719000.00
PHAR income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 1400000.00
PHAR income_statement (annual, 2025-12-31) — Interest Income: 2176000.00
PHAR income_statement (annual, 2025-12-31) — Interest Income Non Operating: 2176000.00
PHAR cash_flow (annual, 2025-12-31) — Interest Paid Cff: -6197000.00
PHAR cash_flow (quarterly, 2025-12-31) — Interest Paid Cff: -2843000.00
PHAR cash_flow (annual, 2025-12-31) — Interest Received Cfo: 2069000.00
PHAR cash_flow (quarterly, 2025-12-31) — Interest Received Cfo: 346000.00
PHAR balance_sheet (annual, 2025-12-31) — Inventory: 64902000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Inventory: 64902000.00
PHAR balance_sheet (annual, 2025-12-31) — Invested Capital: 375157000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Invested Capital: 375157000.00
PHAR cash_flow (annual, 2025-12-31) — Investing Cash Flow: 26252000.00
PHAR cash_flow (quarterly, 2025-12-31) — Investing Cash Flow: -45000.00
PHAR balance_sheet (annual, 2025-12-31) — Investmentin Financial Assets: 6703000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Investmentin Financial Assets: 6703000.00
PHAR balance_sheet (annual, 2025-12-31) — Investments And Advances: 8647000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Investments And Advances: 8647000.00
PHAR balance_sheet (annual, 2025-12-31) — Investmentsin Associatesat Cost: 1944000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Investmentsin Associatesat Cost: 1944000.00
PHAR cash_flow (annual, 2025-12-31) — Issuance Of Debt: 0.00
PHAR cash_flow (quarterly, 2025-12-31) — Issuance Of Debt: 0.00
PHAR balance_sheet (annual, 2025-12-31) — Leases: 6403000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Leases: 6403000.00
PHAR balance_sheet (annual, 2025-12-31) — Long Term Capital Lease Obligation: 14351000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Long Term Capital Lease Obligation: 14351000.00
PHAR balance_sheet (annual, 2025-12-31) — Long Term Debt: 92719000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Long Term Debt: 92719000.00
PHAR balance_sheet (annual, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 107070000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 107070000.00
PHAR cash_flow (annual, 2025-12-31) — Long Term Debt Issuance: 0.00
PHAR cash_flow (quarterly, 2025-12-31) — Long Term Debt Issuance: 0.00
PHAR cash_flow (annual, 2025-12-31) — Long Term Debt Payments: -4245000.00
PHAR cash_flow (quarterly, 2025-12-31) — Long Term Debt Payments: -1368000.00
PHAR balance_sheet (annual, 2025-12-31) — Long Term Equity Investment: 1944000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Long Term Equity Investment: 1944000.00
PHAR balance_sheet (annual, 2025-12-31) — Machinery Furniture Equipment: 19935000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Machinery Furniture Equipment: 19935000.00
PHAR balance_sheet (annual, 2025-12-31) — Minority Interest: 0.00
PHAR balance_sheet (quarterly, 2025-12-31) — Minority Interest: 0.00
PHAR income_statement (annual, 2025-12-31) — Minority Interests: 313000.00
PHAR cash_flow (annual, 2025-12-31) — Net Business Purchase And Sale: -58215000.00
PHAR cash_flow (quarterly, 2025-12-31) — Net Business Purchase And Sale: -8000.00
PHAR income_statement (annual, 2025-12-31) — Net Income: 2851000.00
PHAR income_statement (quarterly, 2025-12-31) — Net Income: 5300000.00
PHAR income_statement (annual, 2025-12-31) — Net Income Common Stockholders: 2851000.00
PHAR income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: 5300000.00
PHAR income_statement (annual, 2025-12-31) — Net Income Continuous Operations: 2538000.00
PHAR income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: 5300000.00
PHAR income_statement (annual, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 2851000.00
PHAR income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 5300000.00
PHAR income_statement (annual, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 2851000.00
PHAR income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 5300000.00
PHAR cash_flow (annual, 2025-12-31) — Net Income From Continuing Operations: 12847000.00
PHAR cash_flow (quarterly, 2025-12-31) — Net Income From Continuing Operations: 4798000.00
PHAR income_statement (annual, 2025-12-31) — Net Income Including Noncontrolling Interests: 2538000.00
PHAR income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: 5300000.00
PHAR cash_flow (annual, 2025-12-31) — Net Intangibles Purchase And Sale: -6000.00
PHAR cash_flow (quarterly, 2025-12-31) — Net Intangibles Purchase And Sale: 0.00
PHAR income_statement (annual, 2025-12-31) — Net Interest Income: -8739000.00
PHAR income_statement (quarterly, 2025-12-31) — Net Interest Income: -1400000.00
PHAR cash_flow (annual, 2025-12-31) — Net Investment Purchase And Sale: 85223000.00
PHAR cash_flow (quarterly, 2025-12-31) — Net Investment Purchase And Sale: 233000.00
PHAR cash_flow (annual, 2025-12-31) — Net Issuance Payments Of Debt: -4245000.00
PHAR cash_flow (quarterly, 2025-12-31) — Net Issuance Payments Of Debt: -1368000.00
PHAR cash_flow (annual, 2025-12-31) — Net Long Term Debt Issuance: -4245000.00
PHAR cash_flow (quarterly, 2025-12-31) — Net Long Term Debt Issuance: -1368000.00
PHAR income_statement (annual, 2025-12-31) — Net Non Operating Interest Income Expense: -8739000.00
PHAR income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: -1400000.00
PHAR cash_flow (annual, 2025-12-31) — Net Other Financing Charges: -7876000.00
PHAR cash_flow (quarterly, 2025-12-31) — Net Other Financing Charges: 0.00
PHAR cash_flow (annual, 2025-12-31) — Net Other Investing Changes: -1000.00
PHAR balance_sheet (annual, 2025-12-31) — Net PPE: 23971000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Net PPE: 23971000.00
PHAR balance_sheet (annual, 2025-12-31) — Net Tangible Assets: 141564000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Net Tangible Assets: 141564000.00
PHAR balance_sheet (annual, 2025-12-31) — Non Current Deferred Assets: 31017000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Assets: 31017000.00
PHAR balance_sheet (annual, 2025-12-31) — Non Current Deferred Taxes Assets: 31017000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Taxes Assets: 31017000.00
PHAR balance_sheet (annual, 2025-12-31) — Non Current Prepaid Assets: 94000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Non Current Prepaid Assets: 94000.00
PHAR income_statement (annual, 2025-12-31) — Normalized EBITDA: 36276000.00
PHAR income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 9406000.00
PHAR income_statement (annual, 2025-12-31) — Normalized Income: 3959548.00
PHAR income_statement (quarterly, 2025-12-31) — Normalized Income: 5300000.00
PHAR cash_flow (annual, 2025-12-31) — Operating Cash Flow: 54708000.00
PHAR cash_flow (quarterly, 2025-12-31) — Operating Cash Flow: 10707000.00
PHAR cash_flow (annual, 2025-12-31) — Operating Gains Losses: -4356000.00
PHAR cash_flow (quarterly, 2025-12-31) — Operating Gains Losses: -4626000.00
PHAR income_statement (annual, 2025-12-31) — Operating Income: 20881000.00
PHAR income_statement (quarterly, 2025-12-31) — Operating Income: 2000000.00
PHAR income_statement (annual, 2025-12-31) — Operating Revenue: 376134000.00
PHAR income_statement (quarterly, 2025-12-31) — Operating Revenue: 106500000.00
PHAR balance_sheet (annual, 2025-12-31) — Ordinary Shares Number: 701680440.00
PHAR balance_sheet (quarterly, 2025-12-31) — Ordinary Shares Number: 701680440.00
PHAR balance_sheet (annual, 2025-12-31) — Other Current Assets: 1000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Other Current Assets: 1000.00
PHAR balance_sheet (annual, 2025-12-31) — Other Current Borrowings: 5336000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Other Current Borrowings: 5336000.00
PHAR balance_sheet (annual, 2025-12-31) — Other Current Liabilities: -1000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Other Current Liabilities: -1000.00
PHAR balance_sheet (annual, 2025-12-31) — Other Equity Adjustments: 28819000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Other Equity Adjustments: 28819000.00
PHAR income_statement (annual, 2025-12-31) — Other Gand A: 18274000.00
PHAR income_statement (quarterly, 2025-12-31) — Other Gand A: 20000000.00
PHAR income_statement (annual, 2025-12-31) — Other Income Expense: 704000.00
PHAR income_statement (quarterly, 2025-12-31) — Other Income Expense: 4200000.00
PHAR balance_sheet (annual, 2025-12-31) — Other Intangible Assets: 132219000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Other Intangible Assets: 132219000.00
PHAR cash_flow (annual, 2025-12-31) — Other Non Cash Items: 13380000.00
PHAR cash_flow (quarterly, 2025-12-31) — Other Non Cash Items: 2291000.00
PHAR balance_sheet (annual, 2025-12-31) — Other Non Current Assets: 1228000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Other Non Current Assets: 1228000.00
PHAR income_statement (annual, 2025-12-31) — Other Non Operating Income Expenses: 1575000.00
PHAR income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: 4200000.00
PHAR income_statement (annual, 2025-12-31) — Other Operating Expenses: 82742000.00
PHAR balance_sheet (annual, 2025-12-31) — Other Properties: 6115000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Other Properties: 6115000.00
PHAR balance_sheet (annual, 2025-12-31) — Other Receivables: 1932000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Other Receivables: 1932000.00
PHAR balance_sheet (annual, 2025-12-31) — Other Short Term Investments: 33796000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Other Short Term Investments: 33796000.00
PHAR income_statement (annual, 2025-12-31) — Other Special Charges: -3877000.00
PHAR balance_sheet (annual, 2025-12-31) — Payables: 14588000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Payables: 14588000.00
PHAR balance_sheet (annual, 2025-12-31) — Payables And Accrued Expenses: 105900000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Payables And Accrued Expenses: 105900000.00
PHAR balance_sheet (annual, 2025-12-31) — Prepaid Assets: 6263000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Prepaid Assets: 6263000.00
PHAR income_statement (annual, 2025-12-31) — Pretax Income: 12847000.00
PHAR income_statement (quarterly, 2025-12-31) — Pretax Income: 4800000.00
PHAR cash_flow (annual, 2025-12-31) — Proceeds From Stock Option Exercised: 19813000.00
PHAR cash_flow (quarterly, 2025-12-31) — Proceeds From Stock Option Exercised: 5249000.00
PHAR balance_sheet (annual, 2025-12-31) — Properties: 0.00
PHAR balance_sheet (quarterly, 2025-12-31) — Properties: 0.00
PHAR cash_flow (annual, 2025-12-31) — Purchase Of Business: -58215000.00
PHAR cash_flow (quarterly, 2025-12-31) — Purchase Of Business: -8000.00
PHAR cash_flow (annual, 2025-12-31) — Purchase Of Intangibles: -6000.00
PHAR cash_flow (quarterly, 2025-12-31) — Purchase Of Intangibles: 0.00
PHAR cash_flow (annual, 2025-12-31) — Purchase Of Investment: -2000.00
PHAR cash_flow (quarterly, 2025-12-31) — Purchase Of Investment: -2000.00
PHAR balance_sheet (annual, 2025-12-31) — Raw Materials: 0.00
PHAR balance_sheet (quarterly, 2025-12-31) — Raw Materials: 0.00
PHAR balance_sheet (annual, 2025-12-31) — Receivables: 48441000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Receivables: 48441000.00
PHAR income_statement (annual, 2025-12-31) — Reconciled Cost Of Revenue: 43493000.00
PHAR income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 21100000.00
PHAR income_statement (annual, 2025-12-31) — Reconciled Depreciation: 11216000.00
PHAR income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 3206000.00
PHAR cash_flow (annual, 2025-12-31) — Repayment Of Debt: -4245000.00
PHAR cash_flow (quarterly, 2025-12-31) — Repayment Of Debt: -1368000.00
PHAR income_statement (annual, 2025-12-31) — Research And Development: 100367000.00
PHAR income_statement (quarterly, 2025-12-31) — Research And Development: 32100000.00
PHAR balance_sheet (annual, 2025-12-31) — Restricted Cash: 761000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Restricted Cash: 761000.00
PHAR balance_sheet (annual, 2025-12-31) — Retained Earnings: -272983000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Retained Earnings: -272983000.00
PHAR income_statement (annual, 2025-12-31) — Salaries And Wages: 92506000.00
PHAR cash_flow (annual, 2025-12-31) — Sale Of Investment: 85225000.00
PHAR cash_flow (quarterly, 2025-12-31) — Sale Of Investment: 235000.00
PHAR income_statement (annual, 2025-12-31) — Selling And Marketing Expense: 6655000.00
PHAR income_statement (quarterly, 2025-12-31) — Selling And Marketing Expense: 31300000.00
PHAR income_statement (annual, 2025-12-31) — Selling General And Administration: 117435000.00
PHAR income_statement (quarterly, 2025-12-31) — Selling General And Administration: 51300000.00
PHAR balance_sheet (annual, 2025-12-31) — Share Issued: 701680440.00
PHAR balance_sheet (quarterly, 2025-12-31) — Share Issued: 701680440.00
PHAR income_statement (annual, 2025-12-31) — Special Income Charges: 3386000.00
PHAR cash_flow (annual, 2025-12-31) — Stock Based Compensation: 13766000.00
PHAR cash_flow (quarterly, 2025-12-31) — Stock Based Compensation: 4510000.00
PHAR balance_sheet (annual, 2025-12-31) — Stockholders Equity: 277102000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Stockholders Equity: 277102000.00
PHAR balance_sheet (annual, 2025-12-31) — Tangible Book Value: 141564000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Tangible Book Value: 141564000.00
PHAR income_statement (annual, 2025-12-31) — Tax Effect Of Unusual Items: -385452.00
PHAR income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
PHAR income_statement (annual, 2025-12-31) — Tax Provision: 10310000.00
PHAR income_statement (quarterly, 2025-12-31) — Tax Provision: -500000.00
PHAR income_statement (annual, 2025-12-31) — Tax Rate For Calcs: 0.26
PHAR income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.26
PHAR balance_sheet (annual, 2025-12-31) — Taxes Receivable: 4742000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Taxes Receivable: 4742000.00
PHAR cash_flow (annual, 2025-12-31) — Taxes Refund Paid: -4599000.00
PHAR cash_flow (quarterly, 2025-12-31) — Taxes Refund Paid: 867000.00
PHAR balance_sheet (annual, 2025-12-31) — Total Assets: 499963000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Total Assets: 499963000.00
PHAR balance_sheet (annual, 2025-12-31) — Total Capitalization: 369821000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Total Capitalization: 369821000.00
PHAR balance_sheet (annual, 2025-12-31) — Total Debt: 115775000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Total Debt: 115775000.00
PHAR balance_sheet (annual, 2025-12-31) — Total Equity Gross Minority Interest: 277102000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Total Equity Gross Minority Interest: 277102000.00
PHAR income_statement (annual, 2025-12-31) — Total Expenses: 355253000.00
PHAR income_statement (quarterly, 2025-12-31) — Total Expenses: 104500000.00
PHAR balance_sheet (annual, 2025-12-31) — Total Liabilities Net Minority Interest: 222861000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Total Liabilities Net Minority Interest: 222861000.00
PHAR balance_sheet (annual, 2025-12-31) — Total Non Current Assets: 200495000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Total Non Current Assets: 200495000.00
PHAR balance_sheet (annual, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 107070000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 107070000.00
PHAR income_statement (annual, 2025-12-31) — Total Operating Income As Reported: 25842000.00
PHAR income_statement (quarterly, 2025-12-31) — Total Operating Income As Reported: 6200000.00
PHAR income_statement (annual, 2025-12-31) — Total Other Finance Cost: 196000.00
PHAR balance_sheet (annual, 2025-12-31) — Total Tax Payable: 6043000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Total Tax Payable: 6043000.00
PHAR income_statement (annual, 2025-12-31) — Total Unusual Items: -1494000.00
PHAR income_statement (annual, 2025-12-31) — Total Unusual Items Excluding Goodwill: -1494000.00
PHAR balance_sheet (annual, 2025-12-31) — Work In Process: 46688000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Work In Process: 46688000.00
PHAR balance_sheet (annual, 2025-12-31) — Working Capital: 183678000.00
PHAR balance_sheet (quarterly, 2025-12-31) — Working Capital: 183678000.00
PHAR income_statement (quarterly, 2026-03-31) — +Operating Expense: 71091000.00
PHAR income_statement (quarterly, 2026-03-31) — +Total Revenue: 72447000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 103526000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 60034000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Additional Paid In Capital: 518601000.00
PHAR income_statement (quarterly, 2026-03-31) — Basic Average Shares: 74471429.00
PHAR income_statement (quarterly, 2026-03-31) — Basic EPS: -0.07
PHAR cash_flow (quarterly, 2026-03-31) — Beginning Cash Position: 145305000.00
PHAR cash_flow (quarterly, 2026-03-31) — Capital Expenditure: -238000.00
PHAR cash_flow (quarterly, 2026-03-31) — Capital Expenditure Reported: -238000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 17440000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Capital Stock: 8065000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 52379000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 170175000.00
PHAR cash_flow (quarterly, 2026-03-31) — Cash Dividends Paid: 0.00
PHAR cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Financing Activities: -9222000.00
PHAR cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Investing Activities: -84760000.00
PHAR cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Operating Activities: 1951000.00
PHAR cash_flow (quarterly, 2026-03-31) — Change In Inventory: -264000.00
PHAR cash_flow (quarterly, 2026-03-31) — Change In Other Working Capital: -181000.00
PHAR cash_flow (quarterly, 2026-03-31) — Change In Payable: 5285000.00
PHAR cash_flow (quarterly, 2026-03-31) — Change In Payables And Accrued Expense: 5285000.00
PHAR cash_flow (quarterly, 2026-03-31) — Change In Receivables: -4395000.00
PHAR cash_flow (quarterly, 2026-03-31) — Change In Working Capital: 445000.00
PHAR cash_flow (quarterly, 2026-03-31) — Changes In Cash: -92031000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Common Stock: 8065000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 268960000.00
PHAR income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 6644000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Current Assets: 295511000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 2770000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Current Debt: 5375000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 8145000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 112346000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Current Provisions: 675000.00
PHAR cash_flow (quarterly, 2026-03-31) — Depreciation: 3116000.00
PHAR cash_flow (quarterly, 2026-03-31) — Depreciation Amortization Depletion: 3116000.00
PHAR cash_flow (quarterly, 2026-03-31) — Depreciation And Amortization: 3116000.00
PHAR income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 74471429.00
PHAR income_statement (quarterly, 2026-03-31) — Diluted EPS: -0.07
PHAR income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: -5213000.00
PHAR income_statement (quarterly, 2026-03-31) — EBIT: -2058000.00
PHAR income_statement (quarterly, 2026-03-31) — EBITDA: 1058000.00
PHAR income_statement (quarterly, 2026-03-31) — Earnings From Equity Interest: -385000.00
PHAR cash_flow (quarterly, 2026-03-31) — Earnings Losses From Equity Investments: 385000.00
PHAR cash_flow (quarterly, 2026-03-31) — Effect Of Exchange Rate Changes: -895000.00
PHAR cash_flow (quarterly, 2026-03-31) — End Cash Position: 52379000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 6580000.00
PHAR cash_flow (quarterly, 2026-03-31) — Financing Cash Flow: -9222000.00
PHAR cash_flow (quarterly, 2026-03-31) — Free Cash Flow: 1714000.00
PHAR cash_flow (quarterly, 2026-03-31) — Gain Loss On Sale Of PPE: 6000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Gains Losses Not Affecting Retained Earnings: 23749000.00
PHAR income_statement (quarterly, 2026-03-31) — General And Administrative Expense: 15217000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 130988000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Gross PPE: 23098000.00
PHAR income_statement (quarterly, 2026-03-31) — Gross Profit: 65803000.00
PHAR income_statement (quarterly, 2026-03-31) — Interest Expense: 2695000.00
PHAR income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 2695000.00
PHAR income_statement (quarterly, 2026-03-31) — Interest Income: 3237000.00
PHAR income_statement (quarterly, 2026-03-31) — Interest Income Non Operating: 3237000.00
PHAR cash_flow (quarterly, 2026-03-31) — Interest Paid Cff: -125000.00
PHAR cash_flow (quarterly, 2026-03-31) — Interest Received Cfo: 379000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Inventory: 64577000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Invested Capital: 367725000.00
PHAR cash_flow (quarterly, 2026-03-31) — Investing Cash Flow: -84760000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Investmentin Financial Assets: 6580000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Investments And Advances: 8113000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 14670000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Long Term Debt: 93390000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 108060000.00
PHAR cash_flow (quarterly, 2026-03-31) — Long Term Debt Payments: -12975000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Long Term Equity Investment: 1533000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Minority Interest: 0.00
PHAR income_statement (quarterly, 2026-03-31) — Minority Interests: 0.00
PHAR cash_flow (quarterly, 2026-03-31) — Net Business Purchase And Sale: 0.00
PHAR balance_sheet (quarterly, 2026-03-31) — Net Debt: 46386000.00
PHAR income_statement (quarterly, 2026-03-31) — Net Income: -5213000.00
PHAR income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: -5213000.00
PHAR income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: -5213000.00
PHAR income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: -5213000.00
PHAR income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: -5213000.00
PHAR cash_flow (quarterly, 2026-03-31) — Net Income From Continuing Operations: -4753000.00
PHAR income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: -5213000.00
PHAR cash_flow (quarterly, 2026-03-31) — Net Intangibles Purchase And Sale: 0.00
PHAR income_statement (quarterly, 2026-03-31) — Net Interest Income: 542000.00
PHAR cash_flow (quarterly, 2026-03-31) — Net Investment Purchase And Sale: -84522000.00
PHAR cash_flow (quarterly, 2026-03-31) — Net Issuance Payments Of Debt: -12975000.00
PHAR cash_flow (quarterly, 2026-03-31) — Net Long Term Debt Issuance: -12975000.00
PHAR income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: 542000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Net PPE: 23098000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 137972000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Assets: 30668000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Assets: 30668000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Non Current Prepaid Assets: 93000.00
PHAR income_statement (quarterly, 2026-03-31) — Normalized EBITDA: 1058000.00
PHAR income_statement (quarterly, 2026-03-31) — Normalized Income: -5213000.00
PHAR cash_flow (quarterly, 2026-03-31) — Operating Cash Flow: 1952000.00
PHAR cash_flow (quarterly, 2026-03-31) — Operating Gains Losses: 391000.00
PHAR income_statement (quarterly, 2026-03-31) — Operating Income: -5288000.00
PHAR income_statement (quarterly, 2026-03-31) — Operating Revenue: 72447000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 706252300.00
PHAR balance_sheet (quarterly, 2026-03-31) — Other Current Borrowings: 5375000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Other Equity Adjustments: 23749000.00
PHAR income_statement (quarterly, 2026-03-31) — Other Gand A: 15217000.00
PHAR income_statement (quarterly, 2026-03-31) — Other Income Expense: -8000.00
PHAR cash_flow (quarterly, 2026-03-31) — Other Non Cash Items: -567000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: 894000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Other Non Current Liabilities: -1000.00
PHAR income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: 377000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Other Properties: 23098000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 117796000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Payables: 103526000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Payables And Accrued Expenses: 103526000.00
PHAR income_statement (quarterly, 2026-03-31) — Pretax Income: -4753000.00
PHAR cash_flow (quarterly, 2026-03-31) — Proceeds From Stock Option Exercised: 3878000.00
PHAR cash_flow (quarterly, 2026-03-31) — Purchase Of Business: 0.00
PHAR cash_flow (quarterly, 2026-03-31) — Purchase Of Intangibles: 0.00
PHAR cash_flow (quarterly, 2026-03-31) — Purchase Of Investment: -102646000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Receivables: 60034000.00
PHAR income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 6644000.00
PHAR income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 3116000.00
PHAR cash_flow (quarterly, 2026-03-31) — Repayment Of Debt: -12975000.00
PHAR income_statement (quarterly, 2026-03-31) — Research And Development: 25557000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Restricted Cash: 725000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Retained Earnings: -281455000.00
PHAR cash_flow (quarterly, 2026-03-31) — Sale Of Investment: 18124000.00
PHAR income_statement (quarterly, 2026-03-31) — Selling And Marketing Expense: 30317000.00
PHAR income_statement (quarterly, 2026-03-31) — Selling General And Administration: 45534000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Share Issued: 706252300.00
PHAR cash_flow (quarterly, 2026-03-31) — Stock Based Compensation: 3225000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 268960000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 137972000.00
PHAR income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
PHAR income_statement (quarterly, 2026-03-31) — Tax Provision: 459000.00
PHAR income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.40
PHAR cash_flow (quarterly, 2026-03-31) — Taxes Refund Paid: -284000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Total Assets: 489365000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 362350000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Total Debt: 116205000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 268960000.00
PHAR income_statement (quarterly, 2026-03-31) — Total Expenses: 77735000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 220405000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 193854000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 108059000.00
PHAR income_statement (quarterly, 2026-03-31) — Total Operating Income As Reported: -4911000.00
PHAR balance_sheet (quarterly, 2026-03-31) — Working Capital: 183165000.00
PHAR.L balance_sheet (annual, 2021-12-31) — Accounts Payable: 7900000.00
PHAR.L balance_sheet (annual, 2021-12-31) — Assets Held For Sale Current: 53700000.00
PHAR.L cash_flow (annual, 2021-12-31) — Common Stock Issuance: 10900000.00
PHAR.L balance_sheet (annual, 2021-12-31) — Current Debt: 33300000.00
PHAR.L balance_sheet (annual, 2021-12-31) — Current Provisions: 3400000.00
PHAR.L income_statement (annual, 2021-12-31) — Interest Income: 0.00
PHAR.L income_statement (annual, 2021-12-31) — Interest Income Non Operating: 0.00
PHAR.L cash_flow (annual, 2021-12-31) — Interest Paid Cfo: -100000.00
PHAR.L cash_flow (annual, 2021-12-31) — Issuance Of Capital Stock: 10900000.00
PHAR.L balance_sheet (annual, 2021-12-31) — Long Term Capital Lease Obligation: 0.00
PHAR.L balance_sheet (annual, 2021-12-31) — Long Term Debt: 47200000.00
PHAR.L balance_sheet (annual, 2021-12-31) — Long Term Debt And Capital Lease Obligation: 47200000.00
PHAR.L cash_flow (annual, 2021-12-31) — Long Term Debt Issuance: 39900000.00
PHAR.L cash_flow (annual, 2021-12-31) — Net Business Purchase And Sale: 2000000.00
PHAR.L balance_sheet (annual, 2021-12-31) — Net Debt: 56100000.00
PHAR.L income_statement (annual, 2021-12-31) — Net Income Discontinuous Operations: 0.00
PHAR.L cash_flow (annual, 2021-12-31) — Net Investment Purchase And Sale: -2200000.00
PHAR.L income_statement (annual, 2021-12-31) — Other Special Charges: 300000.00
PHAR.L cash_flow (annual, 2021-12-31) — Purchase Of Business: 0.00
PHAR.L cash_flow (annual, 2021-12-31) — Purchase Of Investment: -2200000.00
PHAR.L cash_flow (annual, 2021-12-31) — Sale Of Business: 2000000.00
PHAR.L income_statement (annual, 2021-12-31) — Total Other Finance Cost: 2400000.00
PHAR.L income_statement (annual, 2021-12-31) — Write Off: 10400000.00
PHAR.L income_statement (annual, 2022-12-31) — +Operating Expense: 10000000.00
PHAR.L income_statement (annual, 2022-12-31) — +Total Revenue: 199100000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Accounts Payable: 0.00
PHAR.L balance_sheet (annual, 2022-12-31) — Accounts Receivable: 33200000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Accumulated Depreciation: -721100000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Additional Paid In Capital: 158900000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Assets Held For Sale Current: 0.00
PHAR.L income_statement (annual, 2022-12-31) — Basic Average Shares: 439300000.00
PHAR.L income_statement (annual, 2022-12-31) — Basic EPS: 0.06
PHAR.L cash_flow (annual, 2022-12-31) — Beginning Cash Position: 27100000.00
PHAR.L cash_flow (annual, 2022-12-31) — Capital Expenditure: -29800000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Capital Lease Obligations: 800000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Capital Stock: 34300000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Cash And Cash Equivalents: 37900000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Cash Cash Equivalents And Short Term Investments: 37900000.00
PHAR.L cash_flow (annual, 2022-12-31) — Change In Inventory: -900000.00
PHAR.L cash_flow (annual, 2022-12-31) — Change In Payable: -9500000.00
PHAR.L cash_flow (annual, 2022-12-31) — Change In Receivables: -7700000.00
PHAR.L cash_flow (annual, 2022-12-31) — Change In Working Capital: -18100000.00
PHAR.L cash_flow (annual, 2022-12-31) — Changes In Cash: 19600000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Common Stock: 34300000.00
PHAR.L cash_flow (annual, 2022-12-31) — Common Stock Dividend Paid: 0.00
PHAR.L balance_sheet (annual, 2022-12-31) — Common Stock Equity: 330600000.00
PHAR.L cash_flow (annual, 2022-12-31) — Common Stock Issuance: -400000.00
PHAR.L cash_flow (annual, 2022-12-31) — Common Stock Payments: -2900000.00
PHAR.L income_statement (annual, 2022-12-31) — Cost Of Revenue: 116800000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Current Assets: 115500000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Current Capital Lease Obligation: 300000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Current Debt: 39600000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Current Debt And Capital Lease Obligation: 39900000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Current Liabilities: 59100000.00
PHAR.L cash_flow (annual, 2022-12-31) — Depreciation: 55200000.00
PHAR.L cash_flow (annual, 2022-12-31) — Depreciation And Amortization: 55200000.00
PHAR.L income_statement (annual, 2022-12-31) — Diluted Average Shares: 440200000.00
PHAR.L income_statement (annual, 2022-12-31) — Diluted EPS: 0.05
PHAR.L income_statement (annual, 2022-12-31) — Diluted NI Availto Com Stockholders: 24400000.00
PHAR.L cash_flow (annual, 2022-12-31) — Dividends Received Cfi: 0.00
PHAR.L income_statement (annual, 2022-12-31) — EBIT: 87900000.00
PHAR.L income_statement (annual, 2022-12-31) — EBITDA: 143100000.00
PHAR.L cash_flow (annual, 2022-12-31) — Effect Of Exchange Rate Changes: -1400000.00
PHAR.L cash_flow (annual, 2022-12-31) — End Cash Position: 45300000.00
PHAR.L cash_flow (annual, 2022-12-31) — Financing Cash Flow: -19800000.00
PHAR.L cash_flow (annual, 2022-12-31) — Free Cash Flow: 23600000.00
PHAR.L income_statement (annual, 2022-12-31) — General And Administrative Expense: 10000000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Gross PPE: 1120200000.00
PHAR.L income_statement (annual, 2022-12-31) — Gross Profit: 82300000.00
PHAR.L income_statement (annual, 2022-12-31) — Impairment Of Capital Assets: -27900000.00
PHAR.L income_statement (annual, 2022-12-31) — Interest Expense: 7300000.00
PHAR.L income_statement (annual, 2022-12-31) — Interest Expense Non Operating: 7300000.00
PHAR.L cash_flow (annual, 2022-12-31) — Interest Paid Cff: -6000000.00
PHAR.L cash_flow (annual, 2022-12-31) — Interest Received Cfo: 100000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Inventory: 7200000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Invested Capital: 404800000.00
PHAR.L cash_flow (annual, 2022-12-31) — Investing Cash Flow: -14000000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Investmentsin Subsidiariesat Cost: 0.00
PHAR.L cash_flow (annual, 2022-12-31) — Issuance Of Capital Stock: -400000.00
PHAR.L cash_flow (annual, 2022-12-31) — Issuance Of Debt: 16700000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Long Term Capital Lease Obligation: 500000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Long Term Debt: 34600000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Long Term Debt And Capital Lease Obligation: 35100000.00
PHAR.L cash_flow (annual, 2022-12-31) — Long Term Debt Issuance: 16700000.00
PHAR.L cash_flow (annual, 2022-12-31) — Long Term Debt Payments: -27100000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Long Term Equity Investment: 0.00
PHAR.L balance_sheet (annual, 2022-12-31) — Long Term Provisions: 54300000.00
PHAR.L cash_flow (annual, 2022-12-31) — Net Business Purchase And Sale: 18400000.00
PHAR.L cash_flow (annual, 2022-12-31) — Net Common Stock Issuance: -3300000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Net Debt: 36300000.00
PHAR.L income_statement (annual, 2022-12-31) — Net Income: 24400000.00
PHAR.L income_statement (annual, 2022-12-31) — Net Income Common Stockholders: 24400000.00
PHAR.L income_statement (annual, 2022-12-31) — Net Income Continuous Operations: 24400000.00
PHAR.L income_statement (annual, 2022-12-31) — Net Income From Continuing And Discontinued Operation: 24400000.00
PHAR.L income_statement (annual, 2022-12-31) — Net Income From Continuing Operation Net Minority Interest: 24400000.00
PHAR.L cash_flow (annual, 2022-12-31) — Net Income From Continuing Operations: 100200000.00
PHAR.L income_statement (annual, 2022-12-31) — Net Income Including Noncontrolling Interests: 24400000.00
PHAR.L cash_flow (annual, 2022-12-31) — Net Intangibles Purchase And Sale: -4400000.00
PHAR.L income_statement (annual, 2022-12-31) — Net Interest Income: -11400000.00
PHAR.L cash_flow (annual, 2022-12-31) — Net Issuance Payments Of Debt: -10400000.00
PHAR.L cash_flow (annual, 2022-12-31) — Net Long Term Debt Issuance: -27100000.00
PHAR.L income_statement (annual, 2022-12-31) — Net Non Operating Interest Income Expense: -11400000.00
PHAR.L cash_flow (annual, 2022-12-31) — Net Other Investing Changes: 15800000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Net PPE: 399100000.00
PHAR.L cash_flow (annual, 2022-12-31) — Net PPE Purchase And Sale: -25400000.00
PHAR.L cash_flow (annual, 2022-12-31) — Net Short Term Debt Issuance: 16700000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Net Tangible Assets: 330600000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Non Current Deferred Taxes Liabilities: 92900000.00
PHAR.L income_statement (annual, 2022-12-31) — Normalized EBITDA: 122300000.00
PHAR.L income_statement (annual, 2022-12-31) — Normalized Income: 7552000.00
PHAR.L cash_flow (annual, 2022-12-31) — Operating Cash Flow: 53400000.00
PHAR.L income_statement (annual, 2022-12-31) — Operating Income: 72300000.00
PHAR.L income_statement (annual, 2022-12-31) — Operating Revenue: 199100000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Ordinary Shares Number: 430546001.00
PHAR.L balance_sheet (annual, 2022-12-31) — Other Equity Interest: 2100000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Other Investments: 8900000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Other Non Current Assets: -800000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Other Payable: 6300000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Other Properties: 1100000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Other Receivables: 27700000.00
PHAR.L income_statement (annual, 2022-12-31) — Other Special Charges: 6600000.00
PHAR.L income_statement (annual, 2022-12-31) — Otherunder Preferred Stock Dividend: 0.00
PHAR.L balance_sheet (annual, 2022-12-31) — Payables: 11500000.00
PHAR.L income_statement (annual, 2022-12-31) — Pretax Income: 80600000.00